Sino Biopharmaceutical Limited has announced significant progress in its innovation-driven development strategy, as highlighted in a recent voluntary announcement. The company's application for clinical trials of TQB6411, an EGFR/cMet Bispecific ADC, has been accepted by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. Additionally, TQB2922, an EGFR/cMet Bispecific Antibody, has entered Phase I trials, while TQB3002, a Fourth-Generation EGFR Inhibitor, received approval for clinical trials from the United States Food and Drug Administration (FDA) in November of the previous year. These advancements underscore the company's commitment to innovation and its ongoing efforts to enhance its pipeline of clinical-stage assets with First-In-Class and Best-In-Class potential.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。